Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer

Published:2023-12 Issue:8 Volume:24 Page:682-688.e5
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Petranovic Milena,McDermott Shaunagh,Mercaldo Sarah,Little Brent P.,Graur Alexander,Huang Kevin,Fintelmann Florian J.,Digumarthy Subba R.,Gainor Justin F.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. PD-1 and PD-1 ligands: from discovery to clinical application;Okazaki;Int Immunol,2007

2. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review;Khoja;Ann Oncol,2017

3. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis;Wang;JAMA Oncol,2018

4. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors;Suresh;J Thorac Oncol,2018

5. Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study;Suzuki;J Thorac Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities;Cancer Immunology, Immunotherapy;2024-09-05

2. The radiologist’s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review;Insights into Imaging;2024-08-01